gasilhy.blogg.se - Rue mermoz besancon

The score ability to discriminate OS was externally confirmed in 63 (59%) patients with complete clinical data derived from a data set of 106 consecutive LAPC patients median OS of 18.3, 14.1 and 7.6 months for the three groups (log-rank P<0.0001). The PROLAP score has the potential to delineate three different prognosis groups with median OS of 15.4, 11.7 and 8.5 months (log-rank P<0.0001).

The final model had good calibration, acceptable discrimination (C-index=0.60) and robust internal validity. On the basis of the final model, a prognostic nomogram and a score were developed, and externally validated in 106 consecutive LAPC patients treated in Besançon Hospital, France.Īge, pain, tumour size, albumin and CA 19-9 were independent prognostic factors for OS. Performance assessment and internal validation of the final model were done with Harrell's C-index, calibration plot and bootstrap sample procedures. The prognostic ability of 30 baseline parameters was evaluated using univariate and multivariate Cox regression analyses. We address this issue by developing and validating a prognostic nomogram and a score for OS in LAPC (PROLAP).Īnalyses were derived from 442 LAPC patients enrolled in the LAP07 trial. Better discrimination for overall survival (OS) at diagnosis is needed. The management of locally advanced pancreatic cancer (LAPC) patients remains controversial.

15 Department of Digestive Oncology, Beaujon Hospital (AP-HP), 100 boulevard du General Leclerc, Clichy 92110, France.

14 Department of Medical Oncology, Institute Mutualiste Montsouris, 42 Boulevard Jourdan, Paris 75014, France.

13 Department of Medical Oncology, Franco-British Hospital Institute, 3 Rue Barbès, Levallois-Perret 92300, France.

12 Department of Radiotherapy and Medical Oncology, Sainte-Catherine Institute, 250 Chemin de Baigne Pieds, Avignon 84918, France.

11 Department of Medical Oncology, Saint-Antoine Hospital (AP-HP), 184 rue du Faubourg Saint Antoine, Paris 75011, France.

10 Department of Medical Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.

9 Department of Gastroenterology, Jean Mermoz Hospital, 55 avenue Mermoz, Lyon 69008, France.

8 Department of Radiology, Oncology and Radiation Science, University of Uppsala, Uppsala 75105, Sweden.

7 Department of Gastroenterology, Erasme University Hospital, Route de Lennik 808, Brussels 1070, Belgium.

6 AGITG (Australasian Gastrointestinal Trials Group), 119-143 Missenden Rd, Camperdown, New South Wales 2050, Australia.

5 Department of Medical Oncology, Prince of Wales hospital and Prince of Wales Clinical school, UNSW, Sydney, New South Wales 2031, Australia.

4 Department of Gastroenterology, University Hospital of Besançon, 3 Boulevard Alexandre Fleming, Besançon 25030, France.3 Department of Radiotherapy, Tenon Hospital (AP-HP), 4 rue de la Chine, Paris 75020, France.2 Oncology Multidisciplinary Research Group (GERCOR), 151 rue du Faubourg Saint Antoine, Paris 75011, France.1 Methodological and Quality of Life in Oncology Unit, EA 3181, University Hospital of Besançon, 3 Boulevard Alexandre Fleming, Besançon 25030, France.